ReviewCurrent oncology (Toronto, Ont.)2023
Management of Multiple Myeloma: A Review for General Practitioners in Oncology.
Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review.Frontiers in oncology · 2025Pooled it
- Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis.Frontiers in oncology · 2025Pooled it
- A Comparative Analysis of Multiple Myeloma Disease Burden in China and Globally From 1990 to 2023 and Future Trend Projections.Cancer medicine · 2026Article
- Signals in Peripheral Blood: Tracking Redox Status and DNA Damage Response During the Progression of Multiple Myeloma.International journal of molecular sciences · 2026Article
- Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.International journal of hematology · 2026Article
- Identification of Needs of Patients with Multiple Myeloma: A Questionnaire-Based Study in Israeli Patients.Acta haematologica · 2026Article
- The effects of multiple myeloma on total knee arthroplasty outcomes: A retrospective study.Journal of clinical orthopaedics and trauma · 2025Article
- CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization.Cell communication and signaling : CCS · 2025Review
- Polypharmacology: new drugs in 2023-2024.Pharmacological reports : PR · 2025Review
- BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects.Medical oncology (Northwood, London, England) · 2025Review
- The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse.Journal of experimental & clinical cancer research : CR · 2025Article
- Exploring the ocular involvement in multiple myeloma: a comprehensive review of 70-year clinical studies.International ophthalmology · 2025Review
- HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics.Haematologica · 2025Article
- Multiple Myeloma Experiences and Preferences: A Mixed Methods Study of Patients and Care Partners in the United States.Patient preference and adherence · 2025Article
- Gut microbiota in immunomodulation and infection prevention among multiple myeloma patients after chemotherapy: current evidence and clinical prospects.American journal of cancer research · 2025Review
- Optimal cut-off values and diagnostic significance of clinical laboratory indicators in newly diagnosed multiple myeloma.Discover oncology · 2024Article
- Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities.Healthcare (Basel, Switzerland) · 2024Article
- The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma.International journal of molecular sciences · 2024Review
- Multiple myeloma incidence and mortality trends in the United States, 1999-2020.Scientific reports · 2024Article
- Cyclophosphamide, Bortezomib, and Dexamethasone and Severe Systolic Heart Failure: A Case Report.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a malignant clonal plasma cell disorder in the bone marrow and is the second-most common hematologic malignancy in adults. Although patients with MM have a moderate life expectancy, it remains a heterogeneous disease that often requires multiple lines of chemotherapy for durable control and long-term survival. This review outlines current management strategies for both transplant-eligible and transplant-ineligible patients as well as for relapsed and refractory disease. Advances in drug therapies have widened management options and improved survival. In this paper, we also discuss implications for special populations and survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.